Mentioned in ?
References in periodicals archive ?
Armodafinil (Nuvigil) used to treat excessive sleepiness associated with narcolepsy and other sleep disorders is being studied in the Nuvigil Pregnancy Registry (866-404-4106 / www.
Limited Tenders are invited for Supply of Medicine, Acamprosate calcium 333mg, Acarbose 50 mg, Acebrophylline, Alfuzosin 10 mg, Amantadine, Amitriptylline, Aplaphaketoanlogur, Armodafinil, Atenolol, Atorvastatin, B Complex with Zinc, etc.
In addition, you will find news articles about lurasidone, the most recent drug approved for treating bipolar depression, and armodafinil, a sleep drug that is showing efficacy for the depressive component of this vexing disorder.
In addition to showing useful efficacy compared with placebo as adjunctive treatment, armodafinil also had a "very, very benign" adverse effect profile--its 6% dropout rate because of adverse effects was not statistically significant from the 4% rate in placebo patients.
LPI) has received tentative approval for its Armodafinil Tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths as well as another tentative approval for its Doxycycline Capsules, 40 mg (30 mg Immediate-release and 10 mg Delayed-release) from the United States Food and Drugs Administration (FDA).
Statistical superiority to the active comparator 250 mg armodafinil was also found at higher VYVANSE doses.
Armodafinil, the R-enantiomer ofmodafinil, appears equally effective in improving residual sleepiness in CPAP-treated OSA and has a much longer half-life (10-15 h), yet does not appear to interfere with nighttime sleep (98).
Therapeutic use: Armodafinil (6) is the R-enantiomer of modafinil and acts as a central nervous system stimulant.
The 52nd edition features entries for new drugs including Aliskiren, Ambrisentan, Armodafinil, Eculizumab, Lapatinib, Levocetirizine, Retapamulin, and Temsirolimus.
today announced top-line results of its Phase III clinical program for armodafinil (NUVIGIL([R])) as adjunct therapy in adults with major depression associated with bipolar 1 disorder.
BARCELONA - Armodafinil, a drug with Food and Drug Administration approval to treat excessive sleepiness and narcolepsy, showed efficacy for improving concentration, energy, and appetite in a controlled study of nearly 400 patients with bipolar I depression.
The two drugs most beneficial as adjunctive therapy for these patients are modafinil (Provigil) and armodafinil (Nuvigil).